Members of the European
Parliament have voted for a ban on embryonic stem cell research in a vote pitting Catholic conservative members from southern Europe against socialists and liberals from the north. The parliament took the first step that could lead to a ban on a technology focused on the study and potential treatment of genetic diseases.
The practice, which is legal in the UK but banned in many European countries, allows scientists to create human embryonic stem cells or to use human embryos donated by couples undergoing in vitro fertilisation (IVF) treatment which would otherwise be frozen or destroyed.
Although any change in EU legislation will need the support of all 15 current member states, the vote sends a clear message to a broad group of people working in the ethically challenging area of human stem cells. He added: "We hope that EU health ministers will reject these amendments when they are presented with the directive in June." The European Commission is due to debate whether it uses EU money to fund stem cell research projects, and legislation is expected before the end of the year.
The European Parliament's unease about stem cell research followed hot on the heels of ground-breaking judgment by Britain's most senior judges giving the go-ahead to a couple hoping to create a baby whose umbilical cord stem cells could save their four-year-old son's life. The case highlights the tip of the iceberg of ethical and treatment issues in stem cell research. The judges overturned the decision of a lower court to ban the attempt in spite of the go-ahead given two years ago by the Human Fertilisation and Embryology Authority, the body which oversees policy in these areas. Most unusually, the appeal court judges gave the couple the green light ahead of publishing their judgment on how they had reached their decision under the existing law.
In December 2001 Raj and Shahana Hashmi were the first couple in Britain given approval to try to create a sibling who would be a tissue match for a sick brother or sister. But 12 months later, after two failed attempts, they were forced to put any further treatments on ice, when a high court judge ruled that the HFEA had been acting outside its powers in allowing the technique of embryo selection by tissue typing, to go ahead.
We've done everything we can to save Zain's life. Now we all have new hope
The HFEA was criticised last summer by a committee of British MPs for failing to consult the public before deciding to allow the couple to try for a 'designer baby' in the hope of saving the life of an existing child. Ian Gibson, chair of the House of Commons select committee on science and technology said that their report was not an attack on the HFEA. It was, he says, 'a constructive attempt to highlight its weaknesses' so that it could become an organisation that commands respect and confidence.
The case to block the Hashmi's efforts was brought by Josaphine Quintavalle of the 'pro-life' group Comment on Reproductive Ethics, which believes babies should be conceived only for their own benefit and not to help a sibling. The technique involves using IVF to create a number of embryos and then implanting only those which have been shown through tests to be an exact match.
The three appeal court judges overturned the lower court judge's ruling that the HFEA's powers were limited to helping women with fertility problems bear children.The judges made their decision to announce the goahead before the legal ruling because of their appreciation of the highly time-sensitive nature of the case. Mrs Hashmi said: "We're absolutely thrilled. We've done everything a parent could possibly do to try to save Zain's life. Now we all have new hope." She also thought the decision would help other people. "It opens up the door to other families in the same position as us," she said.
The Hashmis were able to go ahead immediately with efforts for new treatment as time is running out for their son, Zain, who has beta thalassemia, a disease that needs frequent blood transfusions for basic management but offers little long-term hope. As Zain gets older, there is less chance that the few stem cells from the umbilical cord would produce a result, and it might then be a question of applying to the court for permission to do a bone marrow transplant with the new sibling as donor. And this was an issue the HFEA was not willing to sanction in its original assessment of selecting embryos for potential uses as cord blood donors so this prospect provides a wholly new, and much more serious, set of ethical hurdles for the HFEA and Zain's parents.
Dr Simon Fishel, director of assisted reproduction at Nottingham Park hospital, who is treating the couple, said he was delighted not only for them but for the other families who had been awaiting the judgment. He said he was advising six couples whose children had disorders that might benefit from the technique.
In spite of the euphoria, he put the Hashmi's chances of finding the right embryo at only about one in 12 and the chances that the embryo would then result in a live child at about one in 10.
The family has sought this treatment route as they have failed to find a suitable bone marrow donor with matching tissue type through conventional transplant services available to patients in such circumstances seeking a potential donor.
Suzi Leather, chair of the HFEA, welcomed the judgment, adding: "Clearly clinicians cannot always prevent diseases but if they are able to and also save the life of a sibling, then this is a legitimate use of these new techniques."
